When Do You Ovulate on Letrozole With PCOS? What Trials Show

How Long After Starting Letrozole Does Ovulation Actually Occur?

Time-to-ovulation ranged from 9 to 22 days after the first letrozole dose in a randomized trial of 148 women with PCOS undergoing their first ovulation-induction cycle, which is the most directly reported answer to this question available in the published trial record. Participants received 5 mg of letrozole daily, for either 5 or 7 days depending on which regimen they were randomly assigned, and were then followed with ultrasound every 2 to 4 days until a follicle larger than 14 mm disappeared or a serum progesterone level rose above 3 ng/mL — the trial’s own definition of a confirmed ovulation, not a guess based on the calendar. Averaged across the women who ovulated, time-to-ovulation was 13.97 ± 2.61 days on the 7-day regimen and 14.11 ± 2.81 days on the 5-day regimen, a difference the trial found was not statistically meaningful (P = 0.84). The mean sits near two weeks; the range around that mean spans thirteen days.

Letrozole works by briefly lowering estrogen, which prompts the pituitary gland to release more follicle-stimulating hormone and drive a follicle toward maturity — the full mechanism, and the live-birth numbers behind why it is now the first-choice ovulation-induction drug in PCOS, are covered in why letrozole became the first-line drug, which this page does not repeat. What that mechanism does not do is fire on a fixed schedule. How quickly a follicle actually matures depends on the individual ovary it starts from, which is the reason a single number can describe a trial average and still be the wrong number for any one woman in it.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. Same condition, same reproductive mechanism — only the label changed. This article uses PCOS, since that is still the term most readers search.

Why Does Ovulation Timing Vary So Much From Woman to Woman?

Higher pre-treatment testosterone, a higher body mass index, and higher anti-Müllerian hormone (AMH) were all significantly linked to a weaker follicular response to letrozole in a prospective cohort of 80 infertile women with PCOS, with an AMH cut-off of 16.43 ng/mL or lower predicting a response with an accuracy (AUC) of 0.88. Of the 80 women in that study, 74 responded to letrozole-based ovulation induction and 6 did not respond at all in the cycle measured. That study measured whether a follicle developed and responded, not precisely how many days a response took, so it explains the between-women variability in the range above only indirectly — but the direction is consistent with it: a follicle starting from a higher-androgen, higher-AMH baseline is the same kind of follicle that, per the physiology described in the letrozole mechanism above, would be expected to take longer to reach maturity if it responds at all.

This is a second, independent reason the single-day version of this answer fails: even setting aside pure biological noise, two women with different baseline hormone profiles are not drawing from the same distribution of likely timing. Neither study above sorted the population by phenotype before reporting its range, so this page cannot tell a reader which end of the 9-to-22-day window her own profile points toward — that reading, done properly, uses an individual’s own labs and monitoring results, not a population average.

Does the Timing Also Vary From Cycle to Cycle in the Same Woman?

No trial behind the range above can answer that question directly, and saying so plainly is more useful than guessing. The 148-woman trial enrolled women undergoing specifically their first ovulation-induction cycle with letrozole, and reported one time-to-ovulation value per woman — not a second, third, or fourth cycle for the same person to compare against her own first result. That is a genuine gap in the published evidence, not an oversight of this article: nobody has published a letrozole trial designed to isolate within-woman, cycle-to-cycle variability in timing the way the trial above isolated variability across different women.

What is documented, in a separate and untreated context, is that the underlying hormonal pattern PCOS produces is itself unstable cycle to cycle. A 32-woman charting study using a standardized basal-temperature and cervical-mucus protocol found the interquartile range of follicular-phase length ran 8 days wider in women with PCOS than in ovulatory controls — meaning the pre-ovulatory phase itself is less predictable in PCOS even with no medication involved. Letrozole does not correct that underlying variability; it acts on top of it. That makes it physiologically plausible that a single woman’s own letrozole-treated cycles would not fall on the same day every time, without a trial existing yet that has actually measured how much.

What Does “You’ll Ovulate Around Day 16” Get Wrong?

A number like day 15 or day 16 shows up often in patient handouts and online summaries of letrozole, usually built by rounding the population average of a standard 5-day, cycle-day-3-to-7 protocol to a single figure. That rounding throws away exactly the information this page exists to restore: the trial that reported the fullest range found ovulation as early as day 9 and as late as day 22 from the first dose, a 13-day spread sitting on either side of that quoted average. A woman who ovulates on day 10 has not responded abnormally, and a woman who has not yet ovulated by day 16 has not necessarily failed to respond — both outcomes sit inside the range a real trial actually observed.

The single-day version of this answer is not wrong because the average is miscalculated; it is wrong because it presents a population mean as if it were a personal prediction. A mean is the center of a distribution, and the distribution above is wide enough that the mean alone tells a reader very little about where her own cycle will land.

So Who Actually Decides When to Test or Expect Ovulation?

Ultrasound and blood work — not a calendar date — are what pinned down the exact day of ovulation for each woman in the trials cited on this page, and that same monitoring is what a prescribing clinician uses to set an individual’s actual timing, not a fixed day counted from the first pill. In the largest trial above, that meant a scan every 2 to 4 days after the last dose until a mature follicle was seen to collapse or progesterone confirmed it had. Confirming ovulation actually happened once treatment is underway follows the same logic as it does in an untreated cycle: a signal-based check beats a date-based guess, and that is truer on letrozole than off it, given the range documented above.

This is also the reason this article stops short of translating any of these numbers into a personal instruction. The 9-to-22-day range, the AMH and BMI associations, and the open question about repeat-cycle variability are all findings about groups of women in published trials. Reading them onto one individual’s own next cycle — deciding from them which day to test, or when to expect ovulation personally — is exactly the kind of interpretation a monitored cycle with a prescribing clinician is designed to do properly, using that person’s own scans and labs rather than someone else’s trial average.

Who Should Expect This Range to Run Long, or Not to Apply at All?

Anyone with a higher baseline AMH, testosterone, or body mass index sits, on the evidence above, closer to the slower-responding or non-responding end of the range — 6 of the 80 women in the predictor cohort did not respond to letrozole at all in the cycle studied, a different and more significant problem than simply ovulating late. The 148-woman timing trial also enrolled a population with a mean BMI of about 23.8 kg/m², solidly in the normal-weight range, so its 9-to-22-day window describes that population most directly and may not transfer cleanly to a higher-BMI phenotype, where the predictor-study findings above suggest a slower or absent response is more likely.

Genuine non-response — no ovulation across several monitored cycles, not simply a wait longer than day 16 — is a different question from the one this page answers, and it is covered along with what to discuss with a clinician about next steps in the full letrozole success-rate breakdown. This page is about how widely a normal, eventually-successful response can vary in timing; it is not evidence about what to do once several fully monitored cycles have not produced ovulation at all. Anyone weighing side effects against this timeline should also see letrozole’s full side-effect profile, and anyone deciding which method to use while waiting to see how a given cycle unfolds may find comparing ovulation-tracking methods for an irregular cycle useful alongside this page. Both are separate questions from the timing range documented here, which is one piece of the complete PCOS fertility hub.

Common questions